Tenaya Therapeutics (TNYA)
(Delayed Data from NSDQ)
$0.67 USD
+0.01 (0.86%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.66 -0.01 (-1.33%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TNYA 0.67 +0.01(0.86%)
Will TNYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TNYA based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for TNYA
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference | ...
TNYA: Chardan Capital Maintains Buy Rating with Price Target of $9.00 | TNYA Stock News
Tenaya Therapeutics GAAP EPS of -$0.14 beats by $0.06
Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c)
Tenaya Therapeutics Inc Reports Q2 2025 EPS of -$0.14, Beating Estimates; Net Loss at $23.3 Million